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CD4+ Cells Treated with DNA Methylation Inhibitors Induce 
Autologous E3 Cell Differentiation 
The DNA methylation inhibitor 5-alacytldinr induces autoreactivity m cloned CD4 7 
T  cells. but the functional consequences of thi\ re\pon\e are unknown. We now report 
that CD4 + T  cells treated with S-azacytidine respond to autologous antigen-presenting 
cells and induce autologous B cell differentiation without exogenous antigen or mitogen. 
This mechanism could play a role in some autoimmune di\eaaes characterized by T  cell 
DNA hypomethylation and polyclonal B cell activation. IWI Acadcn11c Prer,. lnc 
INTRODUCTION 
Despite extensive study, the basic immune mechanism(s) causing lupus remains 
unknown. The murine chronic graft-versu+host model demonstrates that allo- 
reactive CD4+ T cells responding to host class 11 MHC molecules in \*i~o can 
produce a disease resembling systemic lupus erythematosus (SLE) ( I. 3). leading 
some authors to speculate that autoreactive CD4 + cells with class II specificity 
may cause human SLE by a similar mechanism (3). These autoreactive cells have 
been sought in SLE patients using the autologous mixed lymphocyte reaction 
(AMLR), with largely negative results (4-7). Despite this, the concept that au- 
toreactive T cells cause SLE remains attractive since autoreactive cells may be 
distributed in locations other than peripheral venous blood. such as lymphatic 
tissue. or the autoreactive cells may be refractory to restimulation in ~*itro (81, 
preventing their detection. 
Our group has found indirect evidence that autoreactive T cells may be involved 
in the pathogenesis of human SLE. We have reported that cloned antigen-specific 
T cells can become autoreactive following treatment with the DNA methylation 
inhibitor 5-azacytidine (5azaC) (9). Procainamide, which induces a SLE-like syn- 
drome in some patients, also induces autoreactivity in cloned 7’ cells and inhibits 
DNA methylation (IO, 11). Furthermore, patients with active idiopathic SLE have 
recently been found to have hypomethylated T cell DNA (12). These results 
suggest an association between DNA hypomethylation, T cell autoreactivity, and 
SLE. and provide a model in which DNA hypomethylation predisposes to T cell 
autoreactivity, possibly by modifying gene expression, and the autoreactive ‘I 
cells participate in the pathogenesis of the autoimmune disease. However. the 
functional consequences of 5-azaC-induced T cell autoreactivity have not been 
defined. 
The cellular immune abnormalities characterizing SLE include peripheral ve- 
nous B cells actively secreting immunoglobulin and T cells bearing activation 
markers (13-16). The autoreactive and chronic graft-versus-host models provide 
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an explanation for the T cell activation since in both models T cells could be 
activated by class II MHC determinants on B cells, macrophages, or other class 
II bearing cells. The murine chronic graft-versus-host disease model also predicts 
that autoreactive T cells should be able to induce autologous B cells to differen- 
tiate into immunoglobulin-secreting cells, some secreting autoantibodies (2, 17). 
We now report testing the autoreactive model by treating interleukin (IL)- 
2-dependent CD4+ T cell lines with DNA methylation inhibitors, then asking 
whether the treated cells cause autologous B cells to differentiate into immuno- 
globulin-secreting cells. 
MATERIALS AND METHODS 
T Cell Lines 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation as described (9). To obtain CD4+ and CD8+ subsets, 20 x lo6 
freshly isolated PBMC were suspended in 0.5 ml RPM1 1640 and 5 pg OKT4 or 
OKT8 (Ortho Pharmaceuticals, Raritan, NJ) was added. The cells and monoclonal 
antibodies (mAb) were incubated at 4°C 15 min prior to the addition of 0.5 ml 
rabbit complement (Pel-Freeze, Brown Deer, WI). The mixture was incubated at 
37°C for 45 min, the cells were then washed twice in HBSS (GIBCO, Grand 
Island, NY). This treatment was repeated once. T cells were activated with 0.5- 
1.0 kg/ml phytohemagglutinin (PHA) (Burroughs Wellcome, Greenville, NC) in 
RPM1 1640 containing 10% fetal calf serum (FCS) (HyClone, Logan, UT), 100 
U/ml penicillin, and 100 kg/ml streptomycin, and expanded in the same media 
supplemented with IL-2 (conditioned media from MLA-144 cells) (18). Lines were 
cultured .in 24-well plates (Nunc, from GIBCO) and were restimulated weekly by 
adding lo6 irradiated (2OOOR) autologous PBMC to serve as APC plus 10 r&ml 
OKT3 (Ortho Pharmaceuticals). Fresh IL-2 was added twice weekly. 
.Pharmacologic Modification of T Cells 
5-azaC, hydroxyurea, procainamide (all from Sigma Chemical Co., St. Louis, 
MO), and N-acetylprocainamide (Napa) (Aldritch Chemical Co., Milwaukee, WI) 
were added to proliferating T cells, and 6-8 days later the cells were washed and 
used for flow cytometry, proliferation, or B cell differentiation assays. 
Flow Cytometric Analysis 
Fluorescein conjugates of anti-CD4, anti-CD8, anti-2H4, and anti-4B4 were 
purchased from Coulter (Hialeah, FL). Cells were stained with these reagents and 
analyzed on an EPICS V flow cytometer as previously described (19). 
Proliferation Assay 
T cell proliferation was determined by tritiated thymidine ([3H]TdR) incorpo- 
ration as previously described (9-11). Briefly, T cells were washed free of IL-2 
and were cultured 16 hr in RPMI/lO% FCS. T cells (2 x 104) were then cultured 
with 10’ freshly isolated autologous irradiated (2000 R) PBMC in 200 ~1 of 
RPMI/lO% FCS. Two days later, 0.5 &i of 13H]TdR (New England Nuclear, 
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Boston, MA) was added to each well, and 18 hr later the cells were harvested and 
3H incorpora io t n into DNA was determined. All assays were performed in qua- 
druplicate. In some experiments T cells were not precultured in the absence of 
IL-2. In these experiments, proliferation was measured 3 days after setting up the 
assay. No significant differences were observed between the two methods. 
B Cell Differentiation Assay 
All studies were performed with autologous B cells. B cells were isolated from 
PBMC by depletion of adherent and rosette-forming cells as previously described 
and are routinely >95% Ig+ (20). For assay, IL-2-dependent T cell lines were 
washed free of IL-2 and cultured in RPMI/lO% FCS for 1-2 days. T cells (5 x 104) 
were then cultured with 1.25 x lo4 freshly isolated autologous B cells in flat- 
bottomed microtiter wells containing 0.2 ml RPMI/lO% FCS. All cultures were 
performed in quadruplicate. The cultures were fed with an additional SO p,I of 
RPMI/IO% FCS on Days 4 and 8, and on Day 10 the supernatants were harvested 
and stored at - 20°C until assayed for immunoglobulin. 
Antibody Assays 
IgG and IgM in culture supernatants were measured by ELISA as described 
previously (20). The radioimmunoassay for anti-DNA antibodies was performed 
as previously published (21), and the radioimmunoassay for anti-histone antibody 
assay was performed according to the method of Rubin et al. (22). The ELISA for 
antilymphocyte antibodies was performed by washing CD4 + , IL-2-dependent T 
cells, then pipetting 5 x lo5 cells into flat-bottom 96-well Immulon plates (Nunc, 
from GIBCO). The plates were centrifuged at 100~ for 5 min, the media discarded. 
and the cells fixed with 1% glutaraldehyde in 0.01 M PO,, pH 7.4, 0.9% NaCl 
(PBS) for 15 min at 25°C. After three washes with PBS the wells were filled with 
100 ~1 of 2% bovine serum albumin (BSA) (Sigma) in PBS for 1 hr, then antibody 
containing supernatants or serial dilutions of anti-CD2 mAb (Ortho Pharmaceu- 
ticals, Raritan, NJ) were added in 2% BSA/PBS and incubated at 4°C overnight, 
The plates were washed with PBS again, then 80 ~1 protein A-alkaline phos- 
phatase (Sigma) diluted 1:500 in 0.234 M Tris, pH 8.0,O. 1 pM MgCl,, 3 pM NaN,, 
1% hen egg albumin (Sigma) was added for 1 hr. After three washes, 100 pJ 
phosphatase substrate (Sigma) was added at 1 mg/ml in 0.025 M carbonate buffer, 
pH 9.8, and the plates were incubated at 37°C until a color change was apparent. 
The plates were read at 405 nm on a Titertek Multiskan ELISA plate reader. 
Monoclonal Antibodies 
The anti-class I mAb, specific for nonpolymorphic MHC determinants, was 
purchased from Cappel Laboratories (Cochranville, PA). The anti-class II mAb, 
9.49 (23), and the control NS-I ascites were a generous gift from Dr. Robert Todd, 
III. 
Statistical Analysis 
The difference between means was compared using Student’s t test and all 
experiments were repeated two to five times. 
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RESULTS 
SazaC-Treated CD4+ Cells Respond to Autologous APC 
Polyclonal T cells were chosen for these studies, rather than cloned tetanus 
toxoid reactive cells, to more closely approximate in viva immune responses. We 
first established that SazaC-treated polyclonal T cells could respond to autolo- 
gous PBMC. Interleukin-2-dependent, proliferating, polyclonal CD4 + and CD8 + 
cell lines were treated with 1 pJ4 S-azaC for 6-8 days, then challenged with 
irradiated (2000 R) autologous PBMC. The optimal concentration for inducing 
autoreactivity was previously shown to be 1 FM 5-azaC (9). Proliferation was 
measured 3 days later by [3H]TdR incorporation. The results of two experiments 
are shown in Table 1. A small proliferative response to irradiated PBMCs was 
observed in all lines and presumably represents the AMLR. 5-azaC treatment 
markedly increased the proliferative response of CD4 + but not CD8 + cells to 
autologous PBMC. The proliferative response to anti-CD3 mAbs was used as a 
positive control in these experiments, and within each experiment the response to 
anti-CD3 was not significantly different among the lines. 
To test whether class II MHC determinants were required for the CD4+ re- 
sponse, activation of treated CD4+ cells by irradiated autologous APC was in- 
hibited with varying amounts of mAb to class I or class II determinants or a 
control murine ascites (Fig. 1). Anti-class II mAbs were found to abrogate the 
response, while similar concentrations of control ascites did not, and mAb to class 
I determinants in concentrations as high as 100 rig/ml did not significantly inhibit. 
TABLE 1 
RESPONSE OF 5-azaC-TREATED T CELL SUBSETS TO AUTOLOGOUS APC 
Experiment Cells” 
Response (cpm ? SEM)b 
Control 5-azaC 
I CD8 2557 k 322 3692 2 532 
CD4 2037 k 462 18081 t 782 
2 CD8 2727 + 742 1357 k 742 
CD4 2265 t 70 8723 r?- 594 
Note. IL-2-dependent T cell lines were treated with 1 PM 5-azaC and 6-8 days later 20,000 T cells 
were challenged with 16 irradiated autologous PBMC as described under Materials and Methods. 
Proliferation was measured by [3H]TdR incorporation, and results are expressed as the means 2 SEM 
of quadruplicate determinations. 
0 Percentage CD4- and CDI-bearing cells was determined by flow cytometric analysis. In Experi- 
ment 1, the CD8 line contained 86% CD8 + and 7% CD4 + cells, and the CD4 line contained %% 
CD4 + and 1% CD8 + cells. In Experiment 2, the CD8 line contained 99% CD8 + cells, while the CD4 
line had 7% CD8 + cells. 
b The response of control (untreated) or 5-azaC-treated T cells to irradiated PBMC alone is shown. 
Positive controls consisted of the response to PBMC plus anti-CD3 antibodies. The response to 
anti-CD3 was comparable in the experimental lines and was 16,625 ? 1292 in Experiment 1 and 8808 
t 43 1 in Experiment 2 (mean t SEM of the four determinations). Similarly, [3H]TdR uptake by T cells 
cultured alone was 408 2 156 in Experiment 1 and 625 2 413 in Experiment 2. 
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FIG. I. Anti-class 11 mAb inhibit 5-azaC-induced autoreactivity. IL-?-dependent CD4 + cells were 
treated with 1 pJ4 S-azaC and harvested 6 days later. Treated cells (2 x IO41 were then challenged with 
IO5 irradiated autologous PBMC in the presence of the indicated concentrations of mAbs. The anti- 
class I was purchased in purified form and is quantitated in nanograms per milliliter. while the ascites 
form of the anti-class II mAb and control NS-I fusion line ascites were quantitated by dilution. 
Proliferation was measured by [‘H]TdR incorporation and is expressed as the mean cpm 2 SEM of 
quadruplicate determinations. 
Effect of 5-azaC-Treated CD4+ Cells on CD8+ Cells 
Since 5-azaC did not alter CD8+ reactivity, we asked whether CD4+- cells 
could provide help for an autologous response by CD8+ cells. 5-azaC-treated 
CD4 and CD8 cells were mixed in variable ratios and were then challenged with 
irradiated autologous PBMC (Fig. 2). CD8 + cells decreased the CD4 response to 
PBMC, but did not augment or diminish the response beyond that expected by 
diluting the CD4 + cells. In these experiments, anti-CD3-induced proliferation 
was used again as a positive control, and the response to anti-CD3 was similar 
among the lines. Identical results were observed mixing untreated IL-2-dependent 
CD8 + cells with 5-azaC-treated CD4 + cells. 
Effect of S-azaC on 2H4 (CD45R) and 484 (CDw29) Expressiorl 
The response of 5-azaC-treated CD4 + cells to autologous PBMC resembles the 
AMLR, which is also a T cell response to autologous non-T cells without added 
antigen (24). Recent reports indicate that AMLR responsive cells are mainly 
found in the CD4+ 2H4 + subset (25). To test whether 5-azaC selects for the 
2H4+ subset, the CD4+ line was treated with 0.25-2.0 $V 5-azaC and 6 days 
later was tested for 2H4 and 4B4 expression by flow cytometric analysis (Fig. 3). 
Six days was previously shown to be the optimal time to detect 5-azaC-induced 
changes in T cells (19). The untreated CD4 + line was primarily 2H4 - . 5-azaC 
caused a small dose-dependent decrease in 4B4 expression, but did not increase 
2H4 expression. 
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FIG. 2. Effect of mixing SazaC-treated CD4 + and CD8 + cells on autoreactivity. IL-2-dependent 
CD4 and CD8 cell lines were treated with 5-azaC as described in Fig. I. The cells were mixed in the 
proportions indicated on the abscissa and challenged with lo5 irradiated autologous PBMC. Prolifer- 
ation was measured by [‘H]TdR incorporation and results are presented as the means 2 SEM of 
quadruplicate determinations. The response of the CD4 line to 10’ PBMC plus anti-CD3 (10 ngiml) was 
14,304 2 452 cpm and the response of the CD8 line to the same challenge was 19,409 ‘- 2615 cpm. 
[3H]TdR uptake by CD4 cells cultured alone was 106 2 54 cpm, while uptake by the CD8 cells was 621 
* 3 12. Flow cytometric analysis showed that the CD4 line contained 96% CD4 + cells and the CD8 line 
had 86% CD8 + cells. The line labeled “theoretical” connects the proliferative response of CD4 + and 
CD8 + cells cultured separately and represents the results predicted if CD8 + cells were inert in this 
system, and simply diluted the CD4 + population. 
CD#+ Cells Treated with DNA Methylation Inhibitors Induce Autologous B 
Cell Differentiation 
To test whether CD4+ and CD8+ cells treated with DNA methylation inhib- 
itors induced autologous B cell differentiation, CD4+ and CD8+ lines were 
treated with 0.25-2.0 pM 5-azaC, and 6 days later the cells were cultured for an 
additional 2 days without IL-2, then cultured with freshly isolated autologous B 
cells without added antigen or mitogen. Ten days later the supernatants were 
harvested and secreted IgG was measured by ELISA (Fig. 4). Untreated CD4+ 
cells induced secretion of approximately 19 &ml IgG. In contrast, CD4-t cells 
treated with 1 pM 5-azaC induced secretion of 565 rig/ml IgG. Treated CD8 + cells 
did not induce significant IgG secretion. To exclude the possibility that the IgG 
measured reflected B cell lysis and release of presynthesized IgG rather than B 
cell activation, B cells were frozen and thawed and released IgG was measured. 
Under conditions similar to those of the culture system, lysed B cells released 4.9 
+ 0.4 rig/ml IgG. 
To examine whether B cell differentiation required direct T-B contact or could 
be mediated via secreted lymphokines, IL-Zdependent CD4-t cells treated with 
1 pM 5-azaC and untreated control lines were washed free of IL-2 and were 
cultured in RPM1 containing 10% FCS but no IL-2. Two days later the cells were 
removed by centrifugation and 0.2 ml of the lymphokine-enriched supematants 
was added to 5 x lo4 freshly isolated autologous B cells in microtiter wells. Ten 
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FIG. 3. Effect of 5-azaC on 2H4 (CD45R) and 4B4 (CDw29) expression. IL-Ldependent CD4 + cells 
were treated with the indicated concentrations of S-azaC and 6 days later were stained with anti- 
2H4-FITC or anti-4B4-FITC, then analyzed by flow cytometry. 
days later the supernatants were recovered and secreted IgG was measured by 
ELISA as before (Table 2). B cells cultured with media alone secreted less than 
15 rig/ml IgG, and the T cell supernatants also contained less than 15 r&ml IgG. 
B cells cultured with supernatants from freshly isolated, unstimulated CD4 + cells 
from the same T cell donor secreted 27.5 ngiml IgG. In contrast, B cells cultured 
in supematants from proliferating, IL-2-dependent, CD4 + cell lines secreted 1050 
!I-azaC (@I) 
FIG. 4. S-azaC-treated CD4 + cells induce autologous B cell differentiation. IL-2-dependent CD4 + 
(0) and CD8 + (0) lines were treated with the indicated concentrations of 5-azaC. Six days later the 
cells were washed and cultured an additional 2 days without IL-2. T cells (5 x 104) were then cultured 
with 1.25 x lo4 freshly isolated autologous B cells for 10 days in 200 ~1 RPMI/IO% FCS in quadru- 
plicated cultures. Supematants were then harvested and IgG was measured by ELISA. The results 
represent the means 2 SEM of quadruplicate determinations. 
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TABLE 2 
SUPERNATANTS FROM ACTIVATED CD4 + CELLS ACTIVATE AUTOLOGOUS B CELLS 
-- .^-- - - 
T cell supematant” IgG (ng/mllb 
- Cl5 
Unstimulated CD4+ 27.5 2 3.4 
Stimulated CD4 + 1025 5 125 
S-azaC treated, stimulated CD4 + 975 5 125 
u Freshly isolated CD4 + cells obtained from the same donor as the CD4 + lines, IL-2-dependent 
CD4 + cells. or 1 JLM 5-azaC-treated IL-2-dependent CD4 + cells were cultured for 2 days in RPMII 
10% FCS. Supematants from the T cells were then added to freshly isolated autologous B cells as 
described in Fig. 4. 
b Results represent the means 2 SEM of quadruplicate determinations. 
r&ml IgG, and B cells cultured in supernatants from 1 pJ4 5-azaC-treated, pro- 
liferating, IL-2-dependent CD4 + cell lines secreted 975 rig/ml IgG, indicating that 
B cell differentiation can be induced by supematants from activated CD4 + lines, 
regardless of 5-azaC treatment. 
These results suggested that 5-azaC-treated T cells could be activated by au- 
tologous B cells and in turn could activate the B cells by secreted lymphokines. To 
test whether 5-azaC-treated CD4+ cells were activated by the B cells, experi- 
ments similar to those reported in Table I were performed, but using B cells rather 
than PBMC. Treated and untreated CD4+ cells were cultured with irradiated 
(2000 R) autologous B cells with and without anti-CD3 mAbs, and proliferation 
was measured 3 days later by [3H]TdR incorporation. The response of untreated 
CD4+ cells to autologous B cells alone was 6597 + 721 cpm (mean + SEM of 
quadruplicate determinations), and the response of the same cells to B cells plus 
anti-CD3 was 12,522 2 1080 cpm. In contrast, the response of 5-azaC-treated 
CD4+ cells to B cells alone was 11,125 + 695 cpm, while the response to B cells 
and anti-CD3 was 11,248 2 66 cpm, resembling the results presented in Table 1. 
In these experiments, [3H]TdR incorporation by treated and untreated CD4 cells 
cultured alone was less than 1700 cpm. These results suggested that 5-azaC treat- 
ment could make the T cells respond to autologous B cells and secrete lympho- 
kines. 
Alternatively, 5-azaC treatment could cause prolonged lymphokine secretion, 
producing the B cell differentiation observed in coculture experiments. This pos- 
sibility was examined by treating CD4 + cells with 1 piU 5-azaC, and 6 days later 
the cells were washed free of IL-2. Treated and untreated cells were resuspended 
in RPMI/lO% FCS and supematants were collected between 0 and 12, 12 and 24, 
24 and 36, and 36 and 48 hr after removal of IL-2. The supernatants were then 
added to cultured autologous B cells as before, and 10 days later secreted IgG was 
measured. Supematants from treated and untreated cells collected O-12 hr after 
removal of IL-2 produced B cell differentiation, while supernatants collected at 
later times did not. These results indicate that 5-azaC treatment does not result in 
prolonged lymphokine secretion. 
We next compared the effect of other DNA methylation inhibitors on T cells 
using the B cell differentiation assay. Table 3 summarizes the results of experi- 
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TABLE 3 
5-azaC- AND PROCAINAMIDE-TREATED CD4 CELLS INDUCE AUTOLOGOUS B 
CELL DIFFERENTIATION 
Drug” IgG (ng/mllh P 
5-azaC 447 i- lb <. 0.02 
Procainamide 234 + 52 - 0.05 
Napa 106 + 18 -.- 
Hydroxyurea 125 t 20 N.S. 
- 116 _t 21 _ 
” CD4 cells were treated with 0.5-2.0 pM 5-azaC, 10 pM hydroxyurea. 10 uM procainamide, 10 uh4 
Napa, or left untreated t-), then cultured with autologous B cells as described in Fig. 4. 
’ Results represent the means -t SEM of the IgG response of three independent experiments, each 
performed in quadruplicate, comparing 0.5-2.0 pM 5-azaC and 10 PM hydroxyurea with untreated 
cells, and live experiments comparing 10 (LM procainamide and IO (*M Napa. 
’ Results of 5-azaC- and hydroxyurea-treated cells were compared to those obtained with untreated 
cells and results from procainamide-treated cells were compared to those from Napa-treated cells. P 
values were determined using Student’s f  test. N.S.. not significant. 
ments comparing B cell differentiation induced by SazaC, procainamide, Napa, 
hydroxyurea, and untreated CD4+ cells. Hydroxyurea is a DNA synthesis in- 
hibitor that does not inhibit DNA methylation (26), and procainamide is a more 
potent inducer of T cell autoreactivity than Napa (1 I). CD4 + cells were treated 
with 0.5-2.0 pM SazaC, 10 pM hydroxyurea, 10 FM procainamide, or 10 pM 
Napa, then cultured with autologous B cells as before. The highest concentration 
in which IL-2-dependent cells can survive was previously shown to be 10 pM 
hydroxyurea (19), and 10 pM procainamide induces autoreactivity while 10 pM 
Napa does not (11). SazaC- and procainamide-treated CD4 + cells, but not hy- 
droxyurea- or Napa-treated or untreated CD4+ cells, induced significant B cell 
differentiation, as evidenced by IgG secretion. 
Since procainamide induces antilymphocyte (27) and antinuclear antibodies (28) 
in viva, we tested whether IgG induced by 5-azaC- and procainamide-treated 
CD4 + cells contained similar autoantibodies. IgG containing supernatants from B 
cells activated by procainamide- and 5-azaC-treated T cells were tested for anti- 
DNA antibodies using a radioimmunoassay which detected 0.1 rig/ml of anti-DNA 
antibodies in control antisera and none were detected. Antihistone antibodies 
were sought using a radioimmunoassay which detected 0.5 rig/ml control anti- 
histone antibody, and no antihistone antibodies were detected in the B cell su- 
pernatants. Finally, antilymphocyte antibodies were sought using a protein A- 
ELISA technique capable of detecting 1 rig/ml of anti-CD2, using the CD4 + line 
as target, and no antilymphocyte antibodies were detected (data not shown). All 
studies were performed using supernatants containing 300-1000 rig/ml IgG. 
In all the studies presented IgM was also measured. While 5-azaC-treated 
CD4 + cells also induced IgM secretion, the magnitude of the IgM response varied 
widely between experiments, possibly reflecting donor effects (data not shown). 
DISCUSSION 
These experiments demonstrate that 5-azaC-treated polyclonal CD4 + T cell 
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lines respond to autologous PBMC, and that CD4 + cells treated with DNA meth- 
ylation inhibitors induce differentiation in autologous B cells without the addition 
of mitogen or specific antigen. 
Untreated CD4 + and CD8 + lines demonstrated a small proliferative response 
to autologous irradiated PBMC, which presumably is the autologous mixed lym- 
phocyte reaction (24). 5-azaC treatment markedly augmented this response in 
CD4+ lines, but did not alter the CDS+ response. Mixing studies using treated 
CD4 and CD8 + cells demonstrated that the failure of CD8 + cells to respond to 
autologous PBMC was not due to a lack of CD4 + cells. The CD8 + cells did not 
suppress the CD4 response, probably due to difficulties in maintaining suppressor 
cells in long term lines (29). The CD4 + response was inhibited with monoclonal 
antibodies to class II but not class I MHC determinants, suggesting that the cells 
could be responding to autologous HLA-D determinants on the PBMCs. These 
results are similar to previously published experiments in which SazaC-treated, 
cloned tetanus toxoid-specific CD4 + T cells lost the requirement for antigen and 
could be activated by autologous class II determinants alone (9), while 5- 
azaC-treated, cloned CD8+ antigen-specific cells did not demonstrate a similar 
altered reactivity (19). It is reasonable to propose that 5-azaC is inducing autore- 
activity in the polyclonal CD4 + lines by the same mechanism that autoreactivity 
is induced in cloned lines. In other experiments using 5-azaC-treated cloned 
CD4 + cells, the autoreactive response was inhibited with mAb to CD2, CD1 la, 
and ICAM-I, but not CD4 (30), suggesting that molecules of the integrin family are 
also involved in this response. 
Alternatively, in these experiments, 5-azaC treatment may select for AMLR 
responsive cells in polyclonal lines. Recent reports indicate that AMLR respon- 
sive cells are primarily found in the CD4 + 2H4 + population (25). Therefore, we 
tested whether 5-azaC altered the percentage of 2H4+ (CD45R) and 4B4+ 
(CDw29) cells in the polyclonal lines. The untreated lines contained mostly 2H4- 
cells. The low percentage of 2H4 + cells in the untreated lines probably represents 
loss of the 2H4 determinant in these IL-2-dependent lines (31). 5-azaC treatment 
did not increase the percentage of 2H4+ cells, indicating that 5-azaC is not 
selecting this T cell subset. Interestingly, CD4 + 2H4 + cells are also diminished in 
the peripheral blood of SLE patients (32). Furthermore, other investigators have 
reported that CD4+ AMLR responsive cells provide help to AMLR responsive 
CD8 + cells (33, 34). This is not the case in this system, also arguing against a 
selection for AMLR responsive cells. 
While the mechanism by which 5-azaC alters the activation requirements of 
CD4+ cells remains uneertain, the response appears to have functional signifi- 
cance since 5-azaC-treated CD4 + cells reproducibly induced differentiation in 
autologous B cells without the addition of exogenous antigen or mitogen. Hy- 
droxyurea-treated CD4+ cells failed to induce B cell differentiation, consistent 
with previous observations that hydroxyurea does not induce autoreactivity in 
cloned CD4 + cells (9). T cells treated with 10 TV& procainamide also activated B 
cells, but T cells treated with 10 l& Napa did not. The procainamide-treated cells 
presumably induced B cell differentiation via a mechanism similar to 5-azaC since 
cloned T cells treated with 10 FM procainamide become autoreactive, while cells 
378 RICHARDSON, LIEBLING. AND HUDSON 
treated with 10 t~,fr4 Napa do not (11). Significantly, this procainamide concentra- 
tion is close to that achieved therapeutically in vivo (35) and may play a role in the 
B cell activation found in patients with active procainamide-induced SLE (13). 
DNA methylation inhibitors administered in viva could also theoretically di- 
rectly induce B cell differentiation. However, we have treated the B cell line 
RPM1 4265 as well as Epstein-Barr transformed B cells with 5-azaC and found no 
change in IgG or IgM secretion or in expression of surface Ig (unreported obser- 
vations). This suggests that a direct effect of DNA methylation inhibitors on B 
cells is unlikely to be a mechanism responsible for B cell activation. 
Supernatants from activated 5-azaC-treated as well as untreated CD4 -t cells 
induced B cell differentiation, indicating that once the T cells are activated, direct 
B cell binding is no longer required to induce B cell differentiation. The activated 
cells, being largely 2H4 - , 4B4 + , are presumably secreting lymphokines with B 
cell helper activity (36), such as IL-5 (37), IL-6 (38): or interferon-y (20). Studies 
identifying the relevant lymphokines are underway. Decay curves indicated that 
5-azaC treatment did not produce prolonged secretion of lymphokines. These 
results therefore suggest a mechanism for the B cell differentiation observed when 
5-azaC-treated CD4+ cells are cultured with autologous B cells. In this model, 
CD4+ cells treated with DNA methylation inhibitors are activated by self deter- 
minants on B cells, or possibly on contaminating macrophages, and the activated 
T cells secrete lymphokines which in turn induce B cell differentiation. This is 
supported by experiments demonstrating that 5-azaC-treated CD4 + cells prolif- 
erate when challenged with autologous B cells. Since T cells from patients with 
idiopathic SLE appear to have hypomethylated DNA, this model may also apply 
to idiopathic SLE. Other authors have reported isolating autoreactive, Ia-specific 
T cell lines which also induce B cell differentiation via secreted lymphokines (39, 
40), supporting this model. The relationship of these naturally occurring autore- 
active cells to 5-azaC-treated cells remains to be determined. 
Procainamide-induced and idiopathic SLE are also characterized by anti-DNA, 
antihistone, and antilymphocyte antibodies (27, 28, 41). These were sought in 
supernatants from B cells activated by 5-azaC- and procainamide-treated T cells 
and none were found. If autoantibodies were synthesized, they were present in 
amounts too small to detect. The assays could detect nanogram amounts of au- 
toantibodies, and the supernatants contained more than 100 rig/ml of IgG, indi- 
cating that any autoantibodies would account for less than 1% of the secreted IgG. 
However, the B cell donor in these experiments was a healthy volunteer without 
risk factors for autoimmune disease. In patients with autoimmune diseases or 
receiving procainamide, in vivo priming to nuclear antigens could occur (42, 43). 
Exposure to self-antigens in vivo, together with lymphokines supporting B cell 
differentiation, could enrich for autoantibody-secreting B cells in patients with 
SLE. It will be important to repeat these studies in patients with autoimmune 
diseases and controls to test this hypothesis. Furthermore, precursor frequency 
analysis for autoantibodies in idiopathic SLE indicates that B cells making anti- 
DNA antibodies are present at approximately 0.36 per lo6 PBMC (44), while there 
are approximately 4000 Ig-secreting cells/IO6 PBMC in similar patients (45), sug- 
gesting that precursors for anti-DNA antibodies make up only a small fraction of 
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the Ig made in active SLE. This could also explain the low level of autoantibodies 
found in this system. 
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